71837-27-9

Usage

Uses

Used in Pharmaceutical Industry:
Ivermectin B1 Mono-sugar Derivative is used as an impurity in the production of Ivermectin, an antiparasitic drug. It is utilized for its potential therapeutic effects against parasitic infections and as an in vitro inhibitor of SARS-CoV-2, contributing to the development of treatments for COVID-19.
Used in Antiviral Applications:
Ivermectin B1 Mono-sugar Derivative is used as an in vitro inhibitor of SARS-CoV-2, the virus responsible for COVID-19. Its potential antiviral properties make it a candidate for further research and development in the context of COVID-19 treatment and prevention strategies.

Upstream product

• 71827-03-7 5-O-demethyl-22,23-dihydro-avermectin A₁a 

Downstream Products

• 1258313-46-0 C₄₈H₆₇NO₁₂ 
• 1258313-48-2 C₄₈H₆₆ClNO₁₂ 
• 1258313-50-6 C₄₈H₆₆ClNO₁₂ 
• 1258313-52-8 C₄₉H₆₉NO₁₂ 

Relevant academic research and scientific papers

USE OF AVERMECTIN DERIVATIVE FOR INCREASING BIOAVAILABILITY AND EFFICACY OF MACROCYLIC LACTONES

The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of -CH(CH3)2, -CH(CH3)CH2CH3, or cyclohexyle, (ii) X represents -CH2-CH2-, or -CH=CH-, (iii) R2 is chosen from the group constituted of or -OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells

The in vitro characterization of the iterative avermectin glycosyltransferase AveBI reveals reaction reversibility and sugar nucleotide flexibility

The glycosyltransferase AveBI, which is involved in the biosynthesis of the macrolide antihelmintic avermectin (AVM), was characterized in vitro. AveBI was confirmed to catalyze two separate iterative additions of l-oleandrose, and the reversibility of AveBI-catalyzed reaction was also demonstrated. Investigation of sugar nucleotide specificity revealed 10 unique sugar nucleotide substrates which, in combination with five distinct aglycones, led to the production of 50 differentially glycosylated AVM variants. Copyright